Understanding of chest pain in microvascular disease proved by cardiac magnetic resonance image (UMPIRE): study protocol for a randomized controlled trial by unknown
TRIALS
Park et al. Trials 2014, 15:333
http://www.trialsjournal.com/content/15/1/333STUDY PROTOCOL Open AccessUnderstanding of chest pain in microvascular
disease proved by cardiac magnetic resonance
image (UMPIRE): study protocol for a randomized
controlled trial
Sung-Ji Park1†, Jin Joo Park2†, Dong-Ju Choi2*, Eun Ju Chun3, Sang Il Choi3, Sung Mok Kim1, Shin Yi Jang1,
Soyeon Ahn4 and Yeon Hyeon Choe1Abstract
Background: Microvascular angina (MVA) is characterized by anginal chest pain, an abnormal stress test, and
normal coronary arteries on coronary angiography. Although the exact pathogenesis remains unclear, endothelial
dysfunction is a contributing factor. To date, there exists no specific therapy for this disease. Phosphodiesterase-5
inhibitor improves the endothelial function and subsequently microvascular circulation. The aim of this study is to
identify whether udenafil offers benefits in the treatment of MVA in female patients, who have a perfusion defect in
their cardiac magnetic resonance image (CMR), but normal coronary arteries.
Methods/Design: The ‘Understanding of Chest Pain in Microvascular Disease Proved by Cardiac Magnetic Resonance
Image: (UMPIRE)’ trial is a multicenter, prospective, randomized, placebo controlled trial, designed to evaluate the
effect of udenafil on myocardial ischemia and symptoms in female patients with MVA. The myocardial ischemia will
be quantified by myocardial stress perfusion defect in CMR. A total of 80 patients with proven perfusion defect in
adenosine-stress CMR will be randomly assigned to either the udenafil treatment group (daily dose of 100 mg) or the
placebo group for three months. The primary endpoint is >25% improvement in perfusion defect size in adenosine-stress
CMR from baseline. The secondary endpoints include <25% improvement in perfusion defect size, chest pain frequency,
ST depression in stress test, Duke score in stress test, quality of life (QoL) assessment by SF-36 questionnaire, sexual
dysfunction assessment by BISF-W (Brief Index of Sexual Functioning for Women) self-assessment questionnaire, and
biomarkers for endothelial function.
Discussion: The UMPIRE trial is the first randomized controlled trial to evaluate the efficacy of udenafil in female MVA
patients. If udenafil demonstrates cardioprotective effects, it may provide a novel therapeutic option to reduce
myocardial ischemia and improve cardiac function in female MVA patients.
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Figure 1 Study flowchart. CAG; coronary angiography, CTCA;





>25% improvement in perfusion defect size in
adenosine-stress CMR from baseline to three
months after udenafil treatment
Secondary
endpoints
<25% improvement in perfusion defect size in
adenosine-stress CMR from baseline to three
months after udenafil treatment
Decrement of frequency of chest pain
Improvement of ST-depression in stress test
Improvement of Duke score in stress test
Improvement of QoL assessment by SF-36 questionnaire
Improvement of sexual dysfunction assessment
by BISF-W self-questionnaire
Improvement of biomarkers for endothelial function
CMR; Cardiac magnetic resonance image, QoL; Quality of life.
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Microvascular angina (MVA), also known as cardiac
syndrome X, is characterized by anginal chest pain, an
abnormal stress test indicative of myocardial ischemia,
and normal coronary arteries on angiography. The condi-
tion is not as benign as originally reported. While patients
with stable MVA have an excellent prognosis [1], unstable
MVA patients presenting with acute coronary syndrome
have an increased risk of death or myocardial infarction
[2]. Women are more affected than men. The current
therapeutic options for MVA are limited.
An impairment of endothelium-dependent vasodilation
due to reduced nitric oxide (NO) release mainly accounts
for the proposed mechanisms of MVA [3]. NO availability
plays a critical role in the regulation of microvascular
endothelial functions and the arterial structure [4-6].
Many of the biological actions of NO are mediated by
3’5’-guanosine monophosphate (cGMP), which is rapidly
degraded by cGMP phosphodiesterase (PDE). Recently,
phosphodiesterase-5-inhibitor (PDEi) has been reported
to improve the endothelial function in animal and clinical
studies [7-10]. PDE inhibitors improve cardiac perform-
ance in patients with heart failure [11] and reduce infarct
size and attenuate cardiac dysfunction after ischemia/
reperfusion injury or permanent coronary artery occlusion
[12]. While short-term cardiovascular effects of PDE
inhibitors have been studied, the effects of chronic
PDEi administration are not well known, especially in
women with MVA.
In the ‘Understanding of Chest Pain in Microvascular
Disease Proved by Cardiac Magnetic Resonance Image:
(UMPIRE)’ study, we tested whether udenafil offers
benefits in the treatment of female MVA patients who
have a documented perfusion defect in CMR.
Methods/Design
Overview
This trial will be a multicenter, prospective, randomized,
double-blind, placebo controlled trial to demonstrate the
superiority of the therapeutic benefit of low-dose udenafil
over a placebo in the treatment of female MVA patients.
The working hypothesis is ‘udenafil improves vascular
function and, consequently, alleviates ischemia in women
with MVA who have a confirmed perfusion defect in
CMR and normal coronary arteries on coronary CT
angiography (CCTA) or coronary angiography’.
The protocol of the trial has been registered with
Clinicaltrials.gov (registration number: NCT 01769482)
and a brief flowchart of the whole study is summarized
in Figure 1.
Endpoints
The primary endpoint is a >25% improvement from base-
line in perfusion defect size in adenosine-stress CMR afterthree months of udenafil treatment. The secondary end-
points include a <25% improvement in perfusion defect
size, chest pain, quality of life, and sexual functions after
three months of udenafil treatment. Detailed endpoints
are listed in Table 1.Patient population
Patients who are at least 18 years of age, have chest pain
and positive adenosine-stress CMR, and normal coronary
artery on CCTA or coronary angiography will be included
in this study. A positive adenosine-stress CMR is defined
as a perfusion defect of >25% of transmurality. Two high-
volume centers in the Republic of Korea will participate
and enroll eligible patients. The following patients are
excluded from the study: patients with contraindication
to MR contrast media or MR imaging, any heart rhythm
other than sinus rhythm, congestive heart failure, chronic
kidney disease, contraindication to PDEi, or uncontrolled
Table 2 Inclusion and exclusion criteria
Inclusion criteria
1 MVA patients with typical symptom and positive
adenosine-stress CMR and with normal coronary
artery in CCTA or coronary angiography.
2 Definition of positive adenosine-stress CMR:
perfusion defect >25% of transmurality (by
two radiologists based on visual assessment
and qualitative assessment in core-lab)
3 Gender: female
4 Age: 18 to 80-years-old
Exclusion criteria
1 Patient has a contraindication to CMR contrast
media or CMR imaging
2 LVEF <50%
3 Any heart rhythm abnormality other than
sinus rhythm
4 Valvular heart disease with more than moderate degree
5 Renal failure
6 Congestive heart failure
7 Myocardial infraction
8 Myocarditis
9 Congenital heart disease
10 Pericarditis
11 Variant angina (positive provocation
test with ergonovine or acetylcholine)
12 GERD (conformed by esophagogastroduodenoscopy)
13 Pregnant women, suspected pregnant
women or lactating women
14 QT prolongation syndrome or taking drugs
that prolong the QT interval:
- Antiarrhythmics class IA; quinidine, procainamide
- Antiarrhythmics class III; amiodarone, sotalol
15 Pre-analytical within 30 days of screening in a clinical
trial that may affect the influence of udenafil:
- Other PDE-5 inhibitors (for example sildenafil, tadalafil)
- Nitrates/NO donor (for example nitroglycerin,
isosorbide mononitrate, isosorbide dinitrate, amyl
nitrate/nitrite, sodium nitroprusside, and nicorandil)
16 Pre-analytical within seven days of screening in a
clinical trial that may affect the metabolism of udenafil:
- Antibacterials (for example erythromycin)
- Antifungals (for example itraconazole, ketoconazole)




17 Allergy or sensitivity with PDE-5 inhibitors
CCTA; Coronary CT angiography, CMR; Cardiac magnetic resonance image,
GERD; Gastroesophageal reflux disorder, LVEF; Left ventricular ejection fraction,
MVA; Microvascular angina, NO; Nitric oxide, PDE-5; Phosphodiesterase-5.
Park et al. Trials 2014, 15:333 Page 3 of 9
http://www.trialsjournal.com/content/15/1/333diabetes mellitus. The detailed inclusion and exclusion
criteria are summarized in Table 2.
If all of the inclusion criteria are met and none of the
exclusion criteria apply, the patient will be required to
provide written informed consent, as required by the
institutional review board (Samsung Medical Center
Institutional Review Board, Seoul National University
Bundang Hospital Institutional Review Board) in accord-
ance with the Declaration of Helsinki.
Randomization and interventions
After the patients are enrolled in the study, the patients
will be randomized to the udenafil treatment group or the
placebo group by a web-based computerized program
which will be independently managed at T&W software
(Three and Water software, Seoul, Republic of Korea).
The flowchart of the study design is shown in Figure 1.
Udenafil treatment protocol
After random assignment, patients in the udenafil treat-
ment group will receive 100 mg udenafil daily (Dong-
A Pharmaceutical, Seoul, Republic of Korea) for three
months. Since headache and facial flushing are common
side effects of udenafil, the dose of study medication
will be reduced by 50% if severe headache develops. In
patients with serious side effects the study medication
will be stopped.
Cardiac magnetic resonance imaging (CMR)
CMR imaging
Cine imaging All CMR studies will be performed using
a 1.5 T MRI scanner (Siemens Avanto, Erlangen, Germany
or Intera CV release 10; Philips Medical Systems, Best,
Netherlands) with a phased array cardiac coil. Hemo-
dynamic parameters, oxygen saturation, and lead vector
ECG (Electrocardiogram) rhythm will be continuously
monitored throughout the whole CMR exam. Following
image localizers, ventricular long and short axis cine
images will be acquired in end expiration with retrospect-
ively ECG-gated steady-state free precession sequences
(image matrix 128 × 128, read field of view (FOV)
340 mm, phase FOV 75 to 100% of the FOV read, echo
time 1.12 ms, flip angle 70°) with slice thickness 8 mm and
intersection gaps of 12 to 15 mm. The adenosine-stress
CMR protocol is illustrated schematically in Figure 2.
Adenosine infusion protocol Adenosine (Adenoscan™,
Sanofi-Synthelabo, Berlin, Germany) will be infused at
140 μg/kg/min [13], via a 20-gauge cannula sited in an
antecubital vein, using a syringe pump (Graseby™ 3500;
Graseby Medical LTD, Watford, Hertfordshire, UK).
Adenosine will be infused for a minimum of 6 minutes
before acquiring stress images. Indications for terminat-
ing adenosine infusion are persistent or symptomatic
Figure 2 Adenosine-stress CMR protocol. Following image localizers, ventricular long cine images will be acquired. Adenosine (140 mcg/kg/
min) will be infused for 6 minutes before stress perfusion imaging at the time of gadolinium injection. Early gadolinium imaging will be followed
by short axis cine and then rest perfusion imaging. Late gadolinium enhancement images to evaluate the scar and patient viability will conclude
the scan. Study duration will typically be 35 to 40 minutes.
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(systolic blood pressure <90 mmHg), or bronchospasm.
Scans will be supervised by an MRI trained clinician
with access to immediate resuscitation facilities.
Perfusion imaging Patients will undergo pharmacological
stress and rest perfusion. In 1.5 T scanners (Siemens
Avanto, Erlangen, Germany or Intera CV release 10; Philips
Medical Systems, Best, Netherlands), a breath-hold MR
first-pass perfusion examination will be performed. Elec-
trocardiographic gating and triggering will be performed
using the vector cardiographic method. Fast survey images
will be acquired to determine the true short axis of the left
ventricle. After the acquisition of rest cine scans in the
standard views, adenosine will be infused at a dose of
140 μg/kg/min for up to 6 minutes [13]. During the
adenosine infusion, electrocardiographic activity will be
continuously monitored, and blood pressure and heart
rate measurements will be obtained every minute. Within
the last minute of infusion, the adenosine stress MR
perfusion scan will be performed to visualize the three
short-axis slices of 8 mm section thickness using 40
dynamic acquisitions. During the inspiratory phase of
the second breath, a bolus of gadodiamide (Omniscan;
GE healthcare, Pittsburgh, PA, United States) will be
injected using a power injector (Spectris; Medrad,
Indianola, Pennsylvania) into an antecubital vein at a dose
of 0.1 mmol per kilogram of body weight and an injection
rate of 4 ml/s, followed by a 20 mL saline flush. Stress per-
fusion MR images will be obtained with a gradient-echo
sequence by using saturation recovery steady-state free
precession (SR-SSFP). After 15 to 25 minutes, identical
MR perfusion scan at rest will be continued to allow
adequate clearance of the first bolus of the contrast agent.
CMR analysis
Visual analysis Visual analysis of myocardial perfusion will
be performed offline by consensus of two CMR specialists.
Rest and stress perfusion images of the three short axissections (base, mid, and apex) will be viewed side by side.
The first-pass study will be analyzed both in qualitative
and semi-quantitative ways, with a 16-segment left
ventricle model. On qualitative assessment, perfusion
defects are defined as subendocardial or transmural
visually dark myocardial areas, respecting coronary distri-
bution, with a delay of at least 2 seconds compared
with remote healthy myocardium, and persisting for at
least 10 frames [13]. A score will be assigned for each
left ventricular segment according to the following
scale: 0 = no perfusion defect; 1 = subendocardial perfu-
sion defect with transmural extension <25%; 2 = suben-
docardial perfusion defect with transmural extension
between >25% and 50%; 3 = subendocardial perfusion
defect with transmural extension between >50% and 75%;
and 4 = subendocardial perfusion defect with transmural
extension >75%. For each patient a total score will be
obtained as the sum of the individual scores of each
segment. If a perfusion defect is also present at rest, the
stress-related (ischemic) score will be calculated as the
difference between the score after stress minus the
score at rest. All cases will undergo evaluation for late
gadolinium enhancement. A normal scan requires the
absence of both reversible ischemia and late gadolinium
enhancement. A representative example of a patient with
inducible ischemia is shown in Figure 3.
Semi-quantitative analysis Semi-quantitative analysis
will be performed by signal intensity (SI)/time curves
with a commercially available software (QMass MR En-
terprise Solution, Advanced Edition, Medis, Leiden, the
Netherlands); endocardial and epicardial borders of the
three slices are traced manually, and curves and bull’s eye
plots will be obtained by two independent skilled opera-
tors, with divergences being resolved by consensus.
Echocardiography
Two-dimensional transthoracic echocardiography (TTE)
will be performed at patient’s screening and 12 weeks after
Figure 3 A representative example of a patient with inducible ischemia in perfusion CMR. (A) Stress perfusion (B) Rest perfusion. Red
arrow indicates inducible ring-type ischemia in stress perfusion CMR.
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available echocardiographic instrument (Vivid 7, GE
Medical Systems, Milwaukee, Wisconsin, United States or
Sequoia 512, Acuson, Mountain View, California, United
States). A standard M-mode, two-dimensional ECG and
echocardiographic Doppler study will be performed. All
TTE recordings will be interpreted by staff cardiologists.
Follow-up
All patients will visit our outpatient clinic at 1, 4, 8, 12,
and 16 weeks after randomization. Each visit consists of
a clinical evaluation, blood analysis, and a 12-lead ECG.
After three months of udenafil treatment, adenosine-
stress CMR, echocardiography, and a stress test will be
performed (Table 3).
During follow-up visits all adverse events including
chest pain, headache, and so forth, will be documented.
Serious adverse events will be immediately reported to
the principal investigator. To ensure the quality of this
trial, the clinical monitors will survey and document the
trial process once a month in each participating hospital.
Patient dropouts and the reasons, and patients’ compliance
will be recorded at three months after randomization.
Statistical analysis
Sample size calculation
We calculated the sample size for this study using a
superiority categorical variable sample size formula. We
assumed the improvement of perfusion defect size as >25%
in adenosine-stress CMR from baseline to three months
after udenafil treatment. According to the researcher’s
intuition, we assumed the improvement of perfusion
defect as 2% in the control group. If we applied two
tails, an 80% power, an α-level of 0.05, and 10% dropout
rate, we would need a total of 76 patients: 38 patients
in the udenafil treatment arm and 38 patients in the
control arm.The prevalence of variant angina in Asian population
is reported to be between 1 to 5% [14]. For a total of 76
patients, 4 patients with variant angina will possibly be
enrolled in this study. In order to achieve scientifically
robust results, we will enroll a total of 80 patients (40
patients in the udenafil treatment arm and 40 patients in
the control arm).Statistical analysis
For comparison between the udenafil treatment and the
control group, we would use student’s t-test for con-
tinuous variables and χ2-test for categorical variables.
To evaluate improvement of perfusion defect size >25%
between udenafil treatment and control group, we
would analyze using Fisher’s exact test. The difference
in the continuous outcome between the experimental
and control group will be assessed using generalized
linear models. Frequency differences will be tested
using χ2-test or Fisher’s exact test. We will be analyzing
this data using an intention-to-treat analysis. All
randomized patients will be included in the analysis. A
P value of less than 0.05 will be considered statistically
significant.Trial organization
Executive committee
The Executive Committee will be composed of the study
chairperson and the principal investigators of the investi-
gating centers. This committee will approve the final
trial design and protocol issued to the Data and Safety
Monitoring Board (DSMB) and the clinical sites. This
committee will also be responsible for reviewing the final
results, determining the methods of presentation and
publication, and the selection of secondary projects and
publications by members of the Steering Committee.
Table 3 Trial process chart
Visit Visit 1 Visit 2 Visit 3 Visit 4 Visit 5 Visit 6 Visit 7
Status Screening Baseline Follow-up phase






Past medication history1 ●
Family history ●
Randomization ●
Physical examination ● ●
Vital signs ● ● ● ● ●
Height/weight2 ● ● ● ● ●
Blood analysis3 ● ●
Pregnancy test4 ● ●
ECG ● ●
Echocardiography ● ●
Exercise test ● ●
CMR5 ● ●
CAG or CCTA ●
SF-36 questionnaire ● ●
BISF-W self-assessment questionnaire ● ●
Case drug distribution ● ● ●
Case drug collection ● ● ●
Trial evaluation
Adverse events ● ● ● ● ● ● ●
Patient’s compliance ● ● ● ●
Concomitant medications6 ● ● ● ● ●
CMR; Cardiac magnetic resonance image, CAG; Coronary angiography, CCTA; Coronary CT angiography, ECG; Electrocardiogram.
1The participant’s usual medication regimen continued unchanged throughout study duration.
2Check weight only after Visit 2.
3CBC: WBC, Hemoglobin, Hematocrit, Platelet; Chemistry: Total protein, Albumin, Globulin, Total bilirubin, AST; aspartate aminotransferase, ALT; alanine
transaminase, ALP; alkaline phosphatase, BUN; blood urea nitrogen, Creatinine, Uric acid; Electrolyte: Na, K, Cl; NT-proBNP; N-terminal of the prohormone brain
natriuretic peptide; hs-CRP; high-sensitivity c-reactive protein.
(NT-proBNP, hs-CRP: check visit 1 and visit 5).
4Women of child-bearing age.
5Stop all medications three days before CMR.
6Concomitant medications: beta-blockers, calcium channel blockers, angiotensin converting enzyme inhibitors, angiotensin receptor blockers, statin,
and trimetazidine.
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An independent DSMB will be composed of cardiologists
and a biostatistician following the applicable regulatory
guidelines and who did not participate in the trial. The
DSMB committee will review the safety data from this
study and will make recommendations based on safety
analyses of unanticipated device effects (UADEs), serious
adverse events (SAEs), protocol deviation, and follow-up
reports. In addition to the scheduled DSMB meetings
(which will be determined prior to the initiation of thestudy) the board will convene a meeting at any time if
safety problems become an issue. The DSMB are respon-
sible for recommending to the Executive Committee to
modify or stop the study if there are any safety or compli-
ance issues. However, the final decision regarding study
modifications will rest with the Executive Committee.
Cumulative safety data will be reported to the DSMB and
will review on an ongoing basis throughout enrollment
and follow-up to ensure the safety of the patients. Every
effort will be made to allow the DSMB to conduct an
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DSMB reports will be made available to the appropriate
agencies upon request but otherwise will remain strictly
confidential. Prior to the DSMB’s first review of the data,
the DSMB charter will be drafted. This plan defines the
stopping rules for stopping the trial for safety. The first
meeting of the DSMB will be requested for discussion
of the protocol and an understanding of all the protocol
elements. The DSMB will develop a consensus under-
standing of all trial endpoints and definitions used in the
event adjudication process.
Clinical Event Adjudication Committee (CEAC)
The Clinical Events Adjudication Committee (CEAC) is
comprised of cardiologists who are not participants in
the study. The CEAC is responsible for the development
of specific criteria used for the categorization of clinical
events and clinical endpoints in the study, which are
based on protocol. At the onset of the trial, the CEAC
establishes clear rules stating the minimum amount of
data required and the algorithm followed in order to
classify a clinical event. All members of the CEAC are
blinded to the primary results of the trial and meet regu-
larly to review and adjudicate all clinical events in which
the required minimum data is available. The committee
also reviews and rules on all deaths that may occur
throughout the trial.
Data coordination and site management
Data coordination and site management services were
performed by the Clinical Trials Center at Seoul National
University Bundang Hospital.
Ethical approval
The study was approved by the institutional review board
of each center (Samsung Medical Center Institutional
Review Board (approval number 2011-07-048-001), Seoul
National University Bundang Hospital Institutional Review
Board (approval number B-1106-129-016)) and will be
carried out in compliance with the Declaration of Helsinki.
Discussion
Treatment option of MVA
There exist several different therapeutic approaches to
the treatment of MVA. The primary goal of medical
therapy is to ameliorate the chest pain. However, the
conventional anti-anginal treatment is often unsuccessful
in MVA patients [1]. Lanza et al. reported that atenolol
was associated with improvement in chest pain episodes,
while amlodipine and nitrate were not [15,16]. Kaski et al.
reported that angiotensin-converting enzyme inhibition
lessens exercise-induced ischemia in MVA patients [17].
Some authors define MVA as a part of visceral pain syn-
drome which is not related to myocardial ischemia, andreported that imipramine improved the symptoms in
MVA patients, possibly through a visceral analgesic effect
[18]. Taken together, there exists no standard treatment
guideline for MVA.
Rationale for the use of udenafil in MVA patients
The exact pathogenesis for MVA is unknown. However,
it is of note that up to 50% of the resistance to blood
flow in the epicardial coronary artery is determined by
the small coronary blood vessels [19]. Therefore, small
vessels have a significant effect on blood flow in the
large vessels. Endothelial dysfunction, inflammation, and
microcirculation abnormality are the three most commonly
discussed mechanisms for the microvascular dysfunction
[20]. Among them, endothelial dysfunction due to an
impairment of endothelium-dependent vasodilation due
to reduce NO release is the most commonly proposed
mechanism for MVA [3]. NO exerts many of the biological
actions via cGMP, which is rapidly degraded by cGMP
PDE. Thus, PDEi has the potential to improve the endothe-
lial function, which has been shown in animal and clinical
studies [7-10].
Rationale for the udenafil dosage in MVA patients
Udenafil (Zydena™) was developed in 1997 and, after
clinical trials, the drug was approved by the Korea Food
and Drug Administration (KFDA) in 2005. The commer-
cially available and clinically used doses are 100 mg and
200 mg daily. Its half-life time is between 11 and 13 hours,
and the estimated duration of action is approximately
24 hours. Thus, udenafil may be a good candidate drug
for chronic use due to its favorable pharmacokinetic prop-
erties among PDE-5 inhibitors (sildenafil: T1/2 = 2 hours,
duration of action = 4 to 8 hours; tadalafil: T1/2 = 17.5 hours,
duration of action = 36 hours). In phase 3 clinical studies
[21], the 100 mg and 200 mg doses showed similar efficacy
(81 versus 88.5%). However, the side effect rate was lower
with 100 mg daily dosing (flushing: 10 versus 23%, head-
ache: 0 versus 23%, chest discomfort: 0 versus 5.4%, and
so on).
Rationale for the safety of udenafil use in MVA patients
A preclinical trial or phase 1 trial with PDE-5 inhibitors in
coronary vasculature would minimize the risk of potential
candidates being exposed to unnecessary risk. However,
there are plenty of studies reporting the safe use of PDE-5
inhibitors in humans, including those evaluating the effect
of PDE-5 inhibitors on the coronary arteries in humans
[10-12]. There exist at least 11 isoforms of PDE, and the
differential distribution of PDE isoforms in various tissues
is the basis for the potential tissue-specific effect of a PDE
inhibitor. Various tissues have different PDE isoform activ-
ities. Corpus cavernosum contains high activities of PDE
isoforms 2, 3, and 5; human pulmonary circulation has
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PDE isoforms 1, 2, 3, 4, 5 [22]. Consequently, human
coronary arteries can be a target of PDE-5 inhibitors.
In clinical trials, sildenafil contributes little to the
increase in myocardial flow that occurs during exercise
or reactive hyperemia [23], but coronary hemodynamics
and circulation are not unfavorably altered after treatment
with sildenafil and other PDE-5 inhibitors. These study
results imply that PDE-5 inhibitors are safe, but less
likely to be effective. Nevertheless, in patients with
endothelial dysfunction, the PDE-5 inhibitors would lead to
significant hemodynamic improvement. In dysfunctional
endothelium, the release of NO by the endothelium is
significantly compromised [24]. Halcox et al. [25] demon-
strated that coronary arterial segments with endothelial
dysfunction dilated significantly after application of acetyl-
choline combined with sildenafil. This finding infers that
the inhibition of cGMP breakdown by PDE-5 inhibitors
may, at least in part, compensate for reduced NO-related
cGMP production due to endothelial dysfunction. Conse-
quently, in patients with MVA with endothelial dysfunction
the administration of PDE-5 inhibitors may significantly
restore the NO-dependent vasodilation, leading to symp-
tom improvement and improved perfusion in CMR.
Regarding safety concerns, animal studies did not show
any coronary steal phenomenon caused by PDE-5 inhibi-
tors [26,27]. In humans, oral sildenafil produced only
small decreases (<10%) in systemic arterial and pulmonary
arterial pressures, and it had no effect on pulmonary-
capillary wedge pressure, right atrial pressure, heart rate,
or cardiac output. Most importantly, sildenafil did not
alter coronary flow at rest in stenosed arteries and arteries
without angiographically high-grade stenosis, but it
increased coronary flow reserve to a similar extent in
stenosed and non-stenosed arteries (by 13%), rejecting
the possible concern of coronary steel phenomenon
[28]. Halcox et al. [25] also showed a small beneficial
effect on ST-segment depression during exercise testing
in patients with known coronary artery disease. These
studies demonstrate that coronary hemodynamics and
circulation are not unfavorably altered after treatment
with sildenafil and other PDE-5 inhibitors; indeed, coron-
ary blood supply may experience a slight improvement.
Taken together, there exists clinical data that PDE-5
inhibitors are not harmful in coronary artery patients,
and although the effect of PDE-5 inhibitor is limited in
normal coronary circulation, in patients with endothelial
dysfunction the effect of PDE-5 inhibitors may be clinically
significant.
The UMPIRE study is a randomized clinical trial to
investigate the cardioprotective properties of udenafil in
female MVA patients by means of measuring adenosine-
stress perfusion defect size in cardiac MRI. If udenafil
improves myocardial perfusion, udenafil may provide avaluable therapeutic option to reduce myocardial ischemia
and improve cardiac function in female MVA patients.Study limitation
Cardiac syndrome X, or MVA, is generally characterized by
patent coronary tree, chest discomfort (typical or atypical
angina) with positive evidence of a perfusion defect.
Prinzmetal angina patients also complain of chest pain
with a normal coronary tree during an attack-free period.
Thus, if a pharmacologic provocation test (with ergono-
vine or acetylcholine, for example) is not performed, there
will be a risk for enrolling variant angina patients and this
may jeopardize the study. Variant angina patients have
distinctive clinical features that may be used to distinguish
them from MVA patients. First, the chest pain character
differs: while most MVA patients complain of ‘exertional
chest pain’, variant angina patients complain of ‘resting
chest pain’ which often occurs during early morning and
is aggravated by alcohol consumption. Second, variant
angina patients do not have vasospasm during an attack-
free period. Thus, when performing CMR during an attack-
free period, they will have a negative adenosine-stress CMR
and will not be enrolled. Third, even if variant angina
patients have a coronary vasospasm without chest pain,
the perfusion defect in CMR will likely follow a coronary
territory, since there exists a clear vessel preference in
variant angina patients, mostly involving the right cor-
onary artery. Although we may identify variant angina
patients among possible MVA patients by using clinical
characteristics and CMR results, we cannot completely
exclude the possibility of enrolling variant angina patients.
Because the prevalence of variant angina in Asian popu-
lationis reported to be between 1 and 5% [14], we will
increase the sample size from 70 to 76 patients, in order to
achieve scientifically robust results. Despite these measures,
the possibility of enrolling patients with variant angina
remains a major limitation.Trial status
The trial is currently in the recruitment phase. (Recruit-
ment began on 20 November 2012, Expected to finish on
November 2015).
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